Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
STOUGHTON, Mass., July 24, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday,...
-
STOUGHTON, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
-
Xtampza® ER Net Product Revenues of $25.1 million in the First Quarter of 2019, a 59% increase over the First Quarter of 2018 and a 36% increase on a Consecutive-Quarter BasisNet loss of $9.7 million...
-
STOUGHTON, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
-
STOUGHTON, Mass., April 24, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday,...
-
STOUGHTON, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
-
STOUGHTON, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
-
Xtampza® ER Prescriptions Grew 233% in 2018Net Revenue Increased to $73.4 Million for Fourth Quarter 2018 and $280.4 Million for the Full YearCash and Cash Equivalents were $146.6 million as of...
-
STOUGHTON, Mass., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday,...
-
– Xtampza ER Revenue Expected in the Range of $95 Million to $105 Million – Nucynta Franchise Revenue Expected in the Range of $200 Million to $210 Million – Total Operating Expenses Expected in...